Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid decline
Pfizer Inc. (NYSE: PFE) has announced its financial outcomes for the first quarter of 2024, displaying strong performance in its non-COVID product portfolio. This includes heightened revenues from ...
Pfizer beats profit estimates on cost cuts, RSV vaccine sales
Pfizer beat first-quarter profit estimates on Wednesday, benefiting from cost cuts and strong sales for its pneumonia and respiratory synctitial virus vaccines.
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
Pfizer faces challenges with declining COVID-19 product sales and upcoming patent expirations for key products. However, the company's valuation, dividend yield, and overall growth prospects remain...
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
Why Pfizer (PFE) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What Factors Will Drive Pfizer's Q1 Performance?
Pfizer (NYSE: PFE) is scheduled to report its Q1 2024 results on Wednesday, May 1. We expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis.
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte...
Pfizer Receives FDA Approval for Bleeding Disorder Treatment
The treatment, Beqvez, will be available by prescription to eligible patients this quarter.
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
Better Buy: Pfizer vs. Viking Therapeutics
Shares of Pfizer and Viking Therapeutics have been on markedly different trajectories over the prior three years. In this comparison, Pfizer scans as a safer choice for cautious investors, while Vi...
Pfizer (PFE) Rises Higher Than Market: Key Facts
Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.
Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth
Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing...
Pfizer's Doldrums, Just A Bad Case Of COVID-19?
PFE's dividend has reached the sky-high (for a biotech) ~6% mark. Are the dividend and recent share price decline enough to make PFE an attractive play? PFE is following a similar trajectory to GIL...
Why the Market Dipped But Pfizer (PFE) Gained Today
Pfizer (PFE) closed the most recent trading day at $25.91, moving +0.19% from the previous trading session.
Is Pfizer Stock a Buy?
Pfizer has been struggling since its coronavirus vaccine sales started to fall. It's making a big move into cancer drugs, which should help it diversify.
Related Companies